Comparing Moderately and Ultra Hypofractionated Radiation Treatments for Post-operative Prostate Cancer
Key facts
- Where
- London és Toronto, KanadaSee the 3 sites
- Phase
- 2. fázis
Where in Kanada
- London Health Sciences CentreLondon, KanadaTaking people
- Sunnybrook Health Sciences Centre - Sunnybrook Research InstituteToronto, KanadaTaking people
- University Health Network - Princess Margaret Cancer CentreToronto, KanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06409910
- Record updated
- 2026. október 8.
- Original description
This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.Read full original descriptionShow less
A Phase II Randomized Trial: ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY
This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.
Inclusion: Age >/= 18 years; Able to provide informed consent; Histologic diagnosis of prostate adenocarcinoma; ECOG performance status 0-1; Previous radical prostatectomy > 6 months prior to radiotherapy start date; Planned to receive post-operative radiation.
Exclusion: Prior pelvic radiotherapy; Contraindications to radiotherapy; Participants with visible disease in the prostate bed or pelvic lymph nodes on imaging are not eligible for treatment on study; Confirmed metastases (if scan has been done for clinical care).